High Versus Low Dose of Magnesium Sulfate as Initial Tocolytic Agent for Preterm Labour in Symptomatic Placenta Previa.

Assiut University

Status and phase: Completed; Phase 2

Conditions: Placenta Previa Bleeding

Treatments: Drug: Magnesium sulfate

Study type: Interventional

Funder types: Other

Identifiers

NCT04599868

Mgso4 for PTL in pp

Details and patient eligibility

About

To assess the efficacy and safety of alternative magnesium sulfate regimens when used as single agent tocolytic therapy for prevention of preterm labour in patients with symptomatic placenta previa and subsequent changes in the cervical length .

Full description

Placenta previa is implantation of placenta on or near internal os .It is classified into major degree when lower edge of placenta lies within 2 cm from internal os , and minor degree if lower edge of placenta at lower uterine segment but more than 2 cm from internal os .

There are many risk factors for developing placenta previa including multi parity , multiple pregnancy , increased maternal age (>35y ) , previous uterine surgery , history of placenta previa (4-8%) .

A significant degree of uterine contractility has been observed with symptomatic placenta previa. It is directly associated with vaginal bleeding. However, a large percentage of women who have placenta previa associated with haemorrhage will experience subclinical uterine contractions before the onset of overt vaginal bleeding. Therefore, the use of tocolytic agents in management of placenta previa seems reasonable .

Magnesium sulfate alters calcium up take, binding and distribution in smooth muscles of the uterus, so reduces the frequency of cell depolarization and inhibits myometrial contraction .

In addition to its tocolytic action magnesium sulfate also provide neuroprotection to preterm infant . .

At women Health Hospital, Assiut University, Egypt our policy is using magnesium sulfate as first line for tocolysis for placenta previa patients with preterm uterine contractions. By giving a loading dose of 4 g on 150 ml saline intravenous infusion over 20 minutes, and a maintenance dose of 6g/6h on 500 ml saline slow intra venous infusion

Enrollment: 130 patients

Sex: Female

Ages: 16 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Singleton pregnancy.
2. Gestational age between 28 weeks to 37 weeks.
3. Patients presented to the hospital with per vaginal bleeding and in whom a clinical diagnosis of placenta previa is confirmed by trans vaginal ultrasound.
4. Placenta previa with preterm uterine contractions (< 3 contractions in 10 minutes)
5. Ability to provide informed consent.

Exclusion criteria

1. Placental abruption .
2. Women with placenta previa and severe attack of bleeding need immediate termination
3. Clinical criteria of intra uterine infection.
4. intrauterine growth restriction .
5. Fetal anomalies.
6. Fetal distress.
7. intrauterine fetal death.
8. Preterm rupture of membrane
9. High order multiple pregnancies.
10. Treatment with any tocolytic agent before maternal transport.
11. Inability or refusal to provide informed consent.
12. Women with any contraindication for use of magnesium sulfate as patients with renal failure.
13. Patients with bleeding disorder or on anticoagulant therapy .

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

130 participants in 2 patient groups

Low dose of magnesium sulfate group

Active Comparator group

Description:

patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 1g / h

Treatment:

Drug: Magnesium sulfate

High dose of magnesium sulfate group

Active Comparator group

Description:

patients will receive 4 g intravenous loading dose of magnesium sulfate on 150 ml saline over 20 minute period. Patients then will receive maintenance therapy with magnesium sulfate 2g/h

Treatment:

Drug: Magnesium sulfate